Plifosir®
Ibrutinib
Therapeutic action
Antineoplastic protein kinase inhibitors
Indications
Mantle cell lymphoma / Chronic lymphocytic leukemia / Small lymphocyte lymphoma / Chronic lymphocytic leukemia / Small lymphocyte lymphoma with 17p deletion / Waldenström macroglobulinemia / Marginal zone lymphoma
Presentation
Hard capsules of 140 mg